CBD OIL 40% CBD WITH PIPERINE NATURA-REMEDY SERIES, 10ml

CBD Oil 40% (10ml)

This high-concentration oil contains 40% CBD (4000 mg per 10 ml), derived from Cannabis sativa L., and is formulated with a full spectrum of natural cannabinoids, terpenes, and other plant compounds. It offers a clean botanical profile, enriched with piperine for enhanced composition.

🌿 Key Features
• 40% CBD – 4000 mg per 10 ml
• Full-spectrum extract from Cannabis sativa L.
• Contains piperine (black pepper extract)
• Natural carrier oils: MCT (C8/C10 triglycerides)
• Neutral, earthy taste from plant terpenes
• No artificial ingredients, preservatives, or solvents

🧪 How to Use
• Shake well before use
• Place 2–5 drops in the mouth, preferably under the tongue
• Hold for 60–90 seconds
• Do not swallow
• Use 2–3 times daily
• Store in a dark environment at room temperature (15–25°C)

🧬 Cannabidiol (CBD) and Scientifically Documented Properties

Cannabidiol (CBD) is a natural phytocannabinoid derived from the Cannabis sativa plant. Unlike tetrahydrocannabinol (THC), CBD is non-psychoactive, making it safe for daily use¹. It interacts with the endocannabinoid system (ECS), which regulates key physiological functions such as anxiety, pain, sleep, and immune balance².

📌 Key Properties Identified in Scientific Literature:
• Anxiety and stress relief: CBD appears to interact with serotonin receptors, contributing to anxiolytic effects³. It has been studied in cases of social anxiety, generalized anxiety disorder, and PTSD.
• Sleep support: Research shows that CBD may improve sleep quality and duration, particularly when sleep disturbances are related to anxiety⁴.
• Anti-inflammatory and analgesic properties: CBD influences CB1, CB2, and TRPV1 receptors, supporting relief from chronic or neuropathic pain and reducing inflammation⁵.
• Physiological balance (homeostasis): By modulating the ECS, CBD may help support general wellbeing and internal balance⁶.
• Antioxidant and immunomodulatory effects: Experimental data suggest CBD may reduce pro-inflammatory cytokines and support immune response⁷.

🦷 CBD in Oral Care Applications

Recent in vitro studies have evaluated CBD for topical use in the oral cavity due to its antimicrobial, anti-inflammatory, and soothing properties⁸:

• Shows antimicrobial activity against common oral pathogens such as Streptococcus mutans and Porphyromonas gingivalis⁸
• Demonstrates effects comparable or superior to chlorhexidine, without side effects like staining⁹
• Well tolerated by oral tissues — no irritation, burning, or discoloration⁸
• Effectively stabilized in carrier oils such as MCT and olive oil, which enhance delivery in oral formulations⁸

Note: This product has been formulated for topical oral use, in accordance with current European legislation on non-psychoactive industrial hemp products (THC < 0.2%)¹⁰. It is registered in the European CPNP database with Notification Number: CPNP 4470963.

The information presented is based on published scientific literature regarding cannabidiol (CBD) as a compound and does not constitute a health claim for the final product. This product is not intended to diagnose, treat, cure, or prevent any disease.

📚 References

1. World Health Organization. (2018). Cannabidiol (CBD) Critical Review Report.

2. Lowe, H. I. C., Toyang, N. J., & McLaughlin, W. (2021). Medicines, 8(6), 44. https://doi.org/10.3390/medicines8060044

3. Blessing, E. M., et al. (2015). Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1

4. Shannon, S., et al. (2019). The Permanente Journal, 23. https://doi.org/10.7812/TPP/18-041

5. Whiting, P. F., et al. (2015). JAMA, 313(24), 2456–2473. https://doi.org/10.1001/jama.2015.6358

6. Nichols, J. M., & Kaplan, B. L. (2020). Cannabis and Cannabinoid Research, 5(1), 12–31. https://doi.org/10.1089/can.2018.0073

7. Kozela, E., et al. (2011). Journal of Neuroimmune Pharmacology, 6(3), 529–540. https://doi.org/10.1111/j.1476-5381.2011.01379.x

8. Stahl, V., & Vasudevan, K. (2020). Cureus, 12(1), e6809. https://doi.org/10.7759/cureus.6809

9. Iffland, K., & Grotenhermen, F. (2017). Cannabis and Cannabinoid Research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034

10. Regulation (EU) No 1307/2013 and Directive 2002/46/EC – EU compliance on hemp and novel foods